The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Yao, Hang Ping ^a   Zhou, Yong Qing ^b   Ma, Qi ^c   Guin, Sunny ^c   Padhye, Snehal S ^c   Zhang, Rui Wen ^c   Wang, Ming Hai ^a,c  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; MONOCLONAL ANTIBODY ZT F2; PROTEASOME; PROTEIN TYROSINE KINASE; RON RECEPTOR TYROSINE KINASE; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; RON PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL STRAIN 3T3; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; ENDOCYTOSIS; ENZYME DEGRADATION; EXON; HUMAN; HUMAN CELL; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; CELL GROWTH; CELL STRAIN HT29; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; PATHOLOGY;

ANIMALIA; MUS; MUS MUSCULUS;

3T3 CELLS; ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; CELL GROWTH PROCESSES; COLONIC NEOPLASMS; HT29 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NIH 3T3 CELLS; RECEPTOR PROTEIN-TYROSINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960176209     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-82     Document Type: Article

References (39)

1. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 1993, 8:1195-1202.
2. Comoglio PM, Tamagnone L, Boccaccio C. Plasminogen-related growth factor and semaphorin receptors: a gene superfamily controlling invasive growth. Exp Cell Res 1999, 253:88-99. 10.1006/excr.1999.4684, 10579914.
3. Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 2008, 100:1-33.
4. Wang MH, Lee W, Luo YL, Weis MT, Yao HP. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol 2007, 213:402-411. 10.1002/path.2245, 17955509.
5. Lee WY, Chen HH, Chow NH, Su WC, Lin PW, Guo HR. Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 2005, 11:2222-2228. 10.1158/1078-0432.CCR-04-1761, 15788670.
6. Lee CT, Chow NH, Su PF, Lin SC, Lin PC, Lee JC. The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Dis Colon Rectum 2008, 51:1268-1274. 10.1007/s10350-008-9297-1, 18536971.
7. Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, Waltz SE, Lowy AM. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 2007, 67:6075-6082. 10.1158/0008-5472.CAN-06-4128, 17616662.
8. Welm AL, Sneddon JB, Taylor C, Nuyten DS, van de Vijver MJ, Hasegawa BH, Bishop JM. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci USA 2007, 104:7570-7575. 10.1073/pnas.0702095104, 1855278, 17456594.
9. Chen YQ, Zhou YQ, Fisher JH, Wang MH. Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo. Oncogene 2002, 21:6382-6386. 10.1038/sj.onc.1205783, 12214279.
10. Peace BE, Toney-Earley K, Collins MH, Waltz SE. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res 2005, 65:1285-1293. 10.1158/0008-5472.CAN-03-3580, 15735014.
11. Zinser GM, Leonis MA, Toney K, Pathrose P, Thobe M, Kader SA, Peace BE, Beauman SR, Collins MH, Waltz SE. Mammary-specific Ron receptor overexpression induces highly metastatic mammary tumors associated with beta-catenin activation. Cancer Res 2006, 66:11967-11974. 10.1158/0008-5472.CAN-06-2473, 17178895.
12. Dussault I, Bellon SF. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Agents Med Chem 2009, 9:221-229.
13. Wang D, Shen Q, Chen YQ, Wang MH. Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. Oncogene 2004, 23:1668-1680. 10.1038/sj.onc.1207282, 15001985.
14. Wang J, Rajput A, Kan JL, Rose R, Liu XQ, Kuropatwinski K, Hauser J, Beko A, Dominquez I, Sharratt EA, Brattain L, Levea C, Sun FL, Keane DM, Gibson NW, Brattain MG. Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem 2009, 284:10912-10922. 10.1074/jbc.M809551200, 2667777, 19224914.
15. Gaudino G, Follenzi A, Naldini L, Collesi C, Santoro M, Gallo KA, Godowski PJ, Comoglio PM. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J 1994, 13:3524-3532. 395256, 8062829.
16. Wang MH, Ronsin C, Gesnel MC, Coupey L, Skeel A, Leonard EJ, Breathnach R. Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science 1994, 266:117-119. 10.1126/science.7939629, 7939629.
17. Han S, Stuart LA, Degen SJ. Characterization of the DNF15S2 locus on human chromosome 3: identification of a gene coding for four kringle domains with homology to hepatocyte growth factor. Biochemistry 1991, 30:9768-9780. 10.1021/bi00104a029, 1655021.
18. Wang MH, Wang D, Chen YQ. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis 2003, 24:1291-1300. 10.1093/carcin/bgg089, 12807733.
19. Gherardi E, Love CA, Esnouf RM, Jones EY. The sema domain. Curr Opin Struct Biol 2004, 14:669-678. 10.1016/j.sbi.2004.10.010, 15582390.
20. Ma Q, Zhang K, Yao HP, Zhou YQ, Padhye S, Wang MH. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence. Int J Oncol 2010, 36:1551-1561.
21. Zhou YQ, He C, Chen YQ, Wang D, Wang MH. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 2003, 22:186-197. 10.1038/sj.onc.1206075, 12527888.
22. Angeloni D, Danilkovitch-Miagkova A, Ivanov SV, Breathnach R, Johnson BE, Leonard EJ, Lerman MI. Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer 2000, 29:147-156. 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.0.CO;2-N, 10959094.
23. Collesi C, Santoro MM, Gaudino G, Comoglio PM. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol 1996, 16:5518-5526. 231551, 8816464.
24. Zhang K, Zhou YQ, Yao HP, Wang MH. Alterations in a defined extracellular region of the RON receptor tyrosine kinase promote RON-mediated motile and invasive phenotypes in epithelial cells. Int J Oncol 2010, 36:255-264.
25. O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, Covino N, Bassi R, Prewett M, Gottfredsen KJ, Thobe MN, Cheng Y, Li Y, Hicklin DJ, Zhu Z, Waltz SE, Hayman MJ, Ludwig DL, Pereira DS. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 2006, 66:9162-9170. 10.1158/0008-5472.CAN-06-0283, 16982759.
26. Zhang Y, Kaplan-Lefko PJ, Rex K, Yang Y, Moriguchi J, Osgood T, Mattson B, Coxon A, Reese M, Kim TS, Lin J, Chen A, Burgess TL, Dussault I. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res 2008, 68:6680-6687. 10.1158/0008-5472.CAN-07-6782, 18701492.
27. Guin S, Yao HP, Wang MH. RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity. Mol Pharm 2010, 7:386-397. 10.1021/mp900168v, 20039696.
28. Xu XM, Wang D, Shen Q, Chen YQ, Wang MH. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene 2004, 23:8464-8474. 10.1038/sj.onc.1207907, 15378025.
29. Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W, Wang MH. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther 2006, 5:1179-1186. 10.4161/cbt.5.9.3073, 16880737.
30. Lu Y, Yao HP, Wang MH. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett 2007, 257:157-164. 10.1016/j.canlet.2007.08.007, 17889431.
31. Sigismund S, Argenzio E, Tosoni D, Cavallaro E, Polo S, Di Fiore PP. Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation. Dev Cell 2008, 15:209-219. 10.1016/j.devcel.2008.06.012, 18694561.
32. Raeppel S, Gaudette F, Mannion M, Claridge S, Saavedra O, Isakovic L, Déziel R, Beaulieu N, Beaulieu C, Dupont I, Nguyen H, Wang J, Macleod AR, Maroun C, Besterman JM, Vaisburg A. Identification of a novel series of potent RON receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2010, 20:2745-2749. 10.1016/j.bmcl.2010.03.073, 20363625.
33. Wang MH, Kurtz AL, Chen Y. Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 2000, 21:1507-1512. 10.1093/carcin/21.8.1507, 10910951.
34. Yoshida T, Okamoto I, Okabe T, Iwasa T, Satoh T, Nishio K, Fukuoka M, Nakagawa K. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Int J Cancer 2008, 122:1530-1538.
35. Prenen H, Tejpar S, Van Cutsem E. New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res 2010, 16:2921-2926. 10.1158/1078-0432.CCR-09-2029, 20460490.
36. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci USA 2005, 102:1915-1920. 10.1073/pnas.0409610102, 548578, 15684082.
37. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci USA 2009, 106:3294-3299. 10.1073/pnas.0812059106, 2651295, 19218427.
38. Hughes JB, Berger C, Rødland MS, Hasmann M, Stang E, Madshus IH. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol Cancer Ther 2009, 8:1885-1892. 10.1158/1535-7163.MCT-09-0291, 19584234.
39. Austin CD, De Mazière AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004, 15:5268-5282. 10.1091/mbc.E04-07-0591, 532009, 15385631.